Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
VolitionRx Limited Releases Letter to Shareholders Including Status Update on Key Clinical Milestone 2018-01-03 21:30
VolitionRx Limited to Attend Conferences in December 2017-12-05 20:30
VolitionRx Limited Announces Third Quarter 2017 Financial Results and Business Update 2017-11-10 05:05
VolitionRx Limited Schedules Third Quarter 2017 Earnings Conference Call and Business Update 2017-11-02 20:30
VolitionRx Announces the Initial Sale of its New Nu.Q(TM) Research Kits 2017-09-22 20:30
VolitionRx Announces its European Colorectal Cancer Strategy 2017-09-20 04:30
VolitionRx to Attend Two Major Conferences in Asia 2017-09-15 19:30
Volition Granted Four Additional Patents 2017-09-14 20:00
VolitionRx Limited to Attend Multiple Conferences in September 2017-09-07 04:30
Volition Signs Agreement with the Institute of Laboratory Medicine of the Technical University of Munich, Germany, to assist in securing large trials in a range of cancers 2017-08-23 04:30
VolitionRx Limited Announces Second Quarter 2017 Financial Results and Business Update 2017-08-10 04:05
VolitionRx Limited Schedules Second Quarter 2017 Earnings Conference Call and Business Update 2017-08-04 04:30
VolitionRx Limited to host a conference call regarding a 13,500 Subject Colorectal Cancer Screening Trial with the Early Detection Research Network of the U.S. National Cancer Institute 2017-07-20 04:30
Volition America, Inc. Announces a Colorectal Cancer Screening Trial containing approximately 13,500 Subjects in Collaboration with the Early Detection Research Network of the U.S. National Cancer Institute 2017-07-18 18:30
Volition to Present at the EuropaColon Advocacy Masterclass and Exhibit at the European Society for Medical Oncology Gastrointestinal Cancer Congress 2017-06-30 21:22
VolitionRx Limited Corrects an Earlier Announcement 2017-06-27 19:30
VolitionRx Limited to Present at Multiple Investor Conferences in June 2017-05-26 18:30
A new publication reports that 91% of colorectal cancers were detected at 90% specificity in a completed prospective trial using Volition's Nu.Q(TM) assays 2017-05-18 21:00
VolitionRx Limited Announces First Quarter 2017 Financial Results and Business Update 2017-05-11 18:30
VolitionRx Limited Announces Final Results from 8000 Patient Clinical Trial in Denmark to Evaluate the Performance of its Nu.Q(TM) Triage Test 2017-05-09 19:30
1 3 4 5 6 7